Obesity
Also known as: overweight · chronic weight management
Obesity has 15 mapped peptide assets across 4 targets.
Targets
View all →GLP-1R
Activates incretin signaling to potentiate glucose-dependent insulin secretion, delay gastric emptying, and reduce appetite.
GIPR
Mediates GIP-dependent insulin secretion; co-agonism with GLP-1R is thought to enhance weight loss and glycemic control.
Glucagon receptor
Activation increases hepatic glucose output and energy expenditure; biased/co-agonist approaches aim to preserve lipid oxidation and satiety without hyperglycemia.
Amylin receptor
Amylin receptor activation reduces food intake via central satiety signaling and slows gastric emptying.
Active assets by stage
View all →| Asset | Stage | Sponsors |
|---|---|---|
| Tirzepatide | Approved | Eli Lilly |
| Semaglutide | Approved | Novo Nordisk |
| Retatrutide | Phase 3 | Eli Lilly |
| Cagrisema | Phase 3 | Novo Nordisk |
| Mazdutide | Phase 3 | Eli Lilly |
| Danuglipron | Phase 2 | Pfizer |
| Survodutide | Phase 2 | Boehringer Ingelheim, Zealand Pharma |
| Maritide | Phase 1/2 | Amgen |
| CT-388 | Phase 1 | Roche |
| GSBR-1290 | Phase 2 | Structure Therapeutics |
| Orforglipron | Phase 3 | Eli Lilly |
| Pemvidutide | Phase 2 | Eli Lilly |
| Efinopegdutide | Phase 2 | Eli Lilly |
| Oral semaglutide | Approved | Novo Nordisk |
Discontinuations
| Asset | Stage | Sponsors |
|---|---|---|
| Lotiglipron | Discontinued | Pfizer |
Trials
View all →| Registry ID | Phase | Title | Status |
|---|---|---|---|
| NCT03954834 | Phase 3 | A Study of Tirzepatide (LY3298176) Compared With Semaglutide in Participants With Type 2 Diabetes | Completed |
| NCT04159132 | Phase 3 | A Study of Tirzepatide for the Treatment of Obesity or Overweight in Participants Without Type 2 Diabetes | Completed |
| NCT04184622 | Phase 3 | A Research Study to Look at How Semaglutide Works Compared to Placebo in People With Overweight or Obesity | Completed |
| NCT05567796 | Phase 3 | A Study of Retatrutide in Participants With Obesity or Overweight | Recruiting |
| NCT05929066 | Phase 3 | A Study to Evaluate the Effect of CagriSema on Body Weight in Adults Living With Overweight or Obesity | Active, not recruiting |
| NCT05564117 | Phase 2 | A Study of Danuglipron in Participants With Type 2 Diabetes | Completed |
| Pfizer-lotiglipron-Ph2 | Phase 2 | A Study of Lotiglipron in Participants With Type 2 Diabetes | Terminated |
| NCT05649174 | Phase 2 | A Study to Evaluate Survodutide in Participants With Non-alcoholic Steatohepatitis (NASH) | Active, not recruiting |
| NCT03548935 | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 133 in Adult Subjects With Overweight/Obesity | Completed |
| Roche-CT388-Ph1 | Phase 1 | A Study of CT-388 in Participants With Obesity or Overweight | Recruiting |
| StructureTx-GSBR1290-Ph1 | Phase 1 | A Study of GSBR-1290 in Healthy Participants and Participants With Type 2 Diabetes | Completed |
| Lilly-orforglipron-Ph3 | Phase 3 | A Study of Orforglipron in Participants With Obesity or Overweight | Recruiting |
Readouts
View all →Clinical trial registry and NEJM publication
Tirzepatide SURPASS-2 delivers superior HbA1c and weight reductions vs semaglutide 1 mg
Clinical trial registry and NEJM publication
Semaglutide 2.4 mg achieves 14.9% mean weight loss in STEP 1
Clinical trial registry and conference presentation
Retatrutide phase 2 shows up to 24.2% mean weight loss at 48 weeks
ClinicalTrials.gov record and conference abstract